Estamos no ar no ! Saiba mais

Bright Minds Biosciences

DRUG

Valor de mercado US$ 506 mi

51,30 USD

-2,91

5,37%

No fechamento Atualizado 16 de out. 16:00 EDT

1 dia

-5,37%

5 dias

-4,81%

1 mês

-13,21%

3 meses

-30,89%

6 meses

-42,13%

No acumulado do ano

-38,53%

1 ano

-22,74%

5 anos

24,21%

10 anos

24,21%

Sobre: Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Funcionários: 25

Saúde Biotecnologia

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 62,5%

Neutro 37,5%

Negativo 0%

Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Foundation for Prader-Willi Research (FPWR) 2026 Research Symposium, October 7-8, and the PWS Family Conference, October 9-10, at the Marriott Philadelphia Downtown.

Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference

Bright Minds Biosciences to Present at Upcoming Conferences

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT: Cantor Global Healthcare Conference 2026 DATE: Wednesday, September 9, 2026 TIME: 1:35pm ET EVENT: H.C.

Bright Minds Biosciences to Present at Upcoming Conferences

Zacks Investment Research

What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?

Does Bright Minds Biosciences Inc. (DRUG) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?

Zacks Investment Research

Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 97% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

Zacks Investment Research

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet

The mean of analysts' price targets for Bright Minds Biosciences Inc. (DRUG) points to a 97.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet

Vistagen Appoints Douglas J. Williamson to its Board of Directors

SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Douglas J.

Vistagen Appoints Douglas J. Williamson to its Board of Directors

Zacks Investment Research

Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

The consensus price target hints at a 107.5% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

Zacks Investment Research

All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy

Bright Minds Biosciences Inc. (DRUG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy

Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:

Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference

Bright Minds Biosciences to Present at Upcoming Conferences

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:

Bright Minds Biosciences to Present at Upcoming Conferences

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™